Accelerating research in Parkinson’s with GBA

The Silverstein Foundation for Parkinson’s with GBA actively pursues and invests in cutting edge research with the goal of discovering new therapies for the treatment of Parkinson’s Disease in glucocerebrosidase (GBA) mutation carriers.

One Foundation. Many Goals.

The Silverstein Foundation for Parkinson’s with GBA has four main goals:

  • To raise awareness around Parkinson’s Disease associated with GBA mutations and relevant clinical trials for mutation carriers;
  • To aggressively seek out new, cutting-edge therapeutic approaches to treating and preventing Parkinson’s in GBA mutation carriers;
  • To engage with clinicians, academic scientists and biotechnology companies to accelerate research and clinical trials in an effort to rapidly bring new therapeutic options to patients;
  • To raise the necessary funds to meet these goals.

We appreciate your support as we work toward our goals. Please visit our donation page.

Initiatives

We are actively involved in
pre-clinical (and soon to be clinical) programs that could be appropriate for GBA mutation carriers.

Research & Clinical Trials

The Foundation is leading the charge in groundbreaking research and clinical trials focused on Parkinson’s with GBA.

In the News

Watch videos and read news
and press releases related
to the Foundation and
Parkinson’s with GBA.

Chat with us on Twitter

Investment banker Brett Kaplan has left Evercore to join NY-based Prevail Therapeutics as CFO. Prevail is a gene therapy biotech focused on Parkinson's disease & other neuro disorders. They raised $75M A earlier this year. OrbiMed & Jonathan Silverstein's @silversteinFNDN seeded.

Load More...